Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LXEO

Lexeo Therapeutics Inc.

Dec 08 • 04:00PM ET

11.59

Dollar change -1.41
Percentage change -10.85	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	51.56%	Shs Outstand	24.67M	Perf Week	-24.50%
Market Cap	285.93M	Forward P/E	-	EPS next Y	-	Insider Trans	9.81%	Shs Float	11.95M	Perf Month	8.93%
Income	-	PEG	-	EPS next Q	-0.69	Inst Own	17.22%	Short Float / Ratio	0.38% / 0.26	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.04M	Perf Half Y	-
Book/sh	-5.82	P/B	-	EPS next Y	-	ROA	-	Target Price	20.80	Perf Year	-
Cash/sh	1.85	P/C	6.28	EPS next 5Y	-	ROE	-	52W Range	9.00 - 17.72	Perf YTD	15.32%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-34.58%	Beta	-
Dividend %	-	Quick Ratio	3.57	Sales past 5Y	79.54%	Gross Margin	-	52W Low	28.78%	ATR	1.46
Employees	-	Current Ratio	3.57	Sales Q/Q	-	Oper. Margin	-	RSI (14)	-	Volatility	15.10% 11.31%
Optionable	No	Debt/Eq	0.31	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.40	Prev Close	13.00
Shortable	Yes	LT Debt/Eq	0.24	Earnings	-	Payout	-	Avg Volume	175.18K	Price	11.59
Recom	1.00	SMA20	-4.43%	SMA50	-2.12%	SMA200	-2.12%	Volume	69,311	Change	-10.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Longitude Capital Partners IV,	10% Owner	Nov 07	Buy	11.00	454,545	4,999,995	2,567,100	Nov 09 08:32 PM
Omega Fund VI, L.P.	10% Owner	Nov 07	Buy	11.00	454,545	4,999,995	2,157,623	Nov 09 08:36 PM
Lundbeckfond Invest A/S	10% Owner	Nov 07	Buy	11.00	227,272	2,499,992	1,835,959	Nov 09 08:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXEO

Lexeo Therapeutics Inc.

Upgrade your FINVIZ experience